These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34727356)

  • 41. Economic Burden of Comorbidities in Patients with Psoriasis in the USA.
    Wu JJ; Suryavanshi M; Davidson D; Patel V; Jain A; Seigel L
    Dermatol Ther (Heidelb); 2023 Jan; 13(1):207-219. PubMed ID: 36402940
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Medication Copayment on Adherence and Discontinuation in Medicare Beneficiaries with Type 2 Diabetes: A Retrospective Administrative Claims Database Analysis.
    Pawaskar MD; Xu L; Tang Y; Puckrein GA; Rajpathak SN; Stuart B
    Diabetes Ther; 2018 Oct; 9(5):1979-1993. PubMed ID: 30143964
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus.
    Abushanab D; Liew D; Marquina C; Al-Badriyeh D; Ademi Z
    Endocr Pract; 2022 Jan; 28(1):16-24. PubMed ID: 34389513
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants.
    Gilligan AM; Franchino-Elder J; Song X; Wang C; Henriques C; Sainski-Nguyen A; Wilson K; Smith DM; Sander S
    Curr Med Res Opin; 2018 Feb; 34(2):285-295. PubMed ID: 29166800
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease.
    Ehlers LH; Lamotte M; Monteiro S; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
    Diabetes Ther; 2021 May; 12(5):1523-1534. PubMed ID: 33856655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first-line oral therapy for type 2 diabetes: A claims-based observational cohort study.
    Olufade T; Jiang L; Israni R; Huang J; Gosmanov AR
    Diabetes Obes Metab; 2021 Dec; 23(12):2741-2751. PubMed ID: 34405521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 48. Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2020 Mar; 23(3):243-251. PubMed ID: 31686551
    [No Abstract]   [Full Text] [Related]  

  • 49. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.
    Ramos M; Cummings MH; Ustyugova A; Raza SI; de Silva SU; Lamotte M
    Diabetes Ther; 2020 Sep; 11(9):2041-2055. PubMed ID: 32700188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data.
    Strand V; Shah R; Atzinger C; Zhou J; Clewell J; Ganguli A; Tundia N
    Curr Med Res Opin; 2020 Jan; 36(1):161-168. PubMed ID: 31433680
    [No Abstract]   [Full Text] [Related]  

  • 51. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
    Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
    Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database Analysis.
    Johnson C; Stephens J; Walker C; Cappelleri JC; Shelbaya A
    Clinicoecon Outcomes Res; 2020; 12():57-67. PubMed ID: 32021340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.
    Bell K; Parasuraman S; Raju A; Shah M; Graham J; Denno M
    J Manag Care Spec Pharm; 2015 Mar; 21(3):220-8a. PubMed ID: 25726031
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.
    Toy EL; Vekeman F; Lewis MC; Oglesby AK; Duh MS
    Curr Med Res Opin; 2015 Aug; 31(8):1561-72. PubMed ID: 26086578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece.
    Ghetti G; Pradelli L; Papageorgiou G; Karpouzos G; Arikan Y
    Clinicoecon Outcomes Res; 2023; 15():97-109. PubMed ID: 36825076
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis.
    Zah V; Pelivanovic J; Tatovic S; Vukicevic D; Imro M; Ruby J; Hurley D
    Clinicoecon Outcomes Res; 2020; 12():635-643. PubMed ID: 33177851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
    Kabadi SM; Near A; Wada K; Burudpakdee C
    Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.
    Gauthier G; Guérin A; Zhdanava M; Jacobson W; Nomikos G; Merikle E; François C; Perez V
    BMC Psychiatry; 2017 Jun; 17(1):222. PubMed ID: 28629442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
    Lokhandwala T; Coutinho AD; Bell CF
    Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate.
    Patel C; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Tandon N; El Khoury AC
    Drugs Real World Outcomes; 2020 Mar; 7(1):19-29. PubMed ID: 31786737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.